Chiropractic News | Chiropractic Magazine
Your Online Chiropractic Community
Chiropractic Social Network - Facebook Chiropractic Social Network - Twitter Chiropractic Social Network - Linkedin Chiropractic Social Network - Pinterest Chiropractic Social Network - Google Plus Chiropractic Social Network - YouTube Chiropractic Social Network - RSS
 
 
Featured Resources:

Resource Centers:(News, information, and tools to support your practice)


Chiropractic News

May 2008

Article Tools
Comment on this story

Share on your Social Network Post to Facebook Post to LinkedIn Post to Twitter

Chiropractic News from Business Wire

Asphelia to Present at C21 BioVentures Conference in Napa, CA

Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on the development of novel therapeutics for the treatment of a variety of immunological disorders, will be presenting at this years tenth annual C21 BioVentures Conference in Napa, CA. C21 is a private lifescience company conference aimed at fostering relationships within the biotechnology, pharmaceutical, and venture capital industries. This years C21 will be held at The Meritage Resort at Napa from May 20th to May 22nd.

Francois-Xavier Frapaise MD, CEO and President of Asphelia, will introduce Asphelias core-assets - namely, a trichuris suis ova-based therapy (ASP 1002) and an oral integrin antagonist (ASP 2002). Dr. Frapaises presentation will be focused on the immunomodulating effects of Helminths and the use of this novel therapeutic approach in the treatment of immunological disorders, such as Crohns

Disease, Multiple Sclerosis, as well as allergic conditions. The Helminths technology is currently being assessed in several clinical studies being conducted globally.

About Asphelia Pharmaceuticals, Inc.

Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelias primary focus lies in its development of therapies targeting Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including multiple sclerosis and asthma. Asphelias lead compounds target the cause of Inflammatory Bowel Disease, not just its symptoms, in an effort to change the course of the diseases and provide patients with new freedoms.





Asphelia Pharmaceuticals, Inc.
Xavier Frapaise, 858-731-8520
xfrapaise@aspheliapharma.com


Share on your social network

Comments


Be the first to comment on this Article

Name
 
Location
 
Comment
Limited to 500 Characters. You have characters left.
To submit your comment, please type the security word shown in the picture. imgCaptcha
Remember information
 
 

 

Chiropractic Economics Magazine - A Chiropractic Publication

Chiropractic News



Campaign for Chiropractic

Chiropractic Economics ©2014 | 5150 Palm Valley Rd. Suite 103 | Ponte Vedra Beach, FL 32082 | P:904.285.6020 F:904.285.9944